CLASS II Drug recall · Reported 28 Apr 2021 · FDA Enforcement Report

Estradiol Transdermal System Delivers 0.0375 mg/day, 8 Systems/box recalled

Noven Pharmaceuticals is recalling Estradiol Transdermal System Delivers 0.0375 mg/day, 8 Systems/box, distributed nationwide in the US. The recall was initiated on 16 Apr 2021 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: 88321 Exp. 02/2022
NDC68968-3410, 68968-3425, 68968-3437, 68968-3450, 68968-3475
Quantity recalled10872 cartons

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0337-2021
FDA event ID
87741
Recalling firm
Noven Pharmaceuticals, Miami, FL
Manufacturer
Noven Therapeutics, LLC
Classification
Class II
Status
Terminated
Recall initiated
16 Apr 2021
FDA classified
20 Apr 2021
Reported
28 Apr 2021
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

16 Apr 2021Recall initiated by company
20 Apr 2021Classified by FDA+4 days
28 Apr 2021Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Estradiol Transdermal System Delivers 0.0375 mg/day, 8 Systems/box, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. by: Noven Therapeutics, LLC Miami, Florida 33186, NDC 68968-3437-8

Where it was distributed

Nationwide within the United States

Nationwide

Questions about this recall

Why was it recalled?

Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Which lots are affected?

Lot #: 88321 Exp. 02/2022

Where was it sold?

Nationwide within the United States

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 87741
ReportedClassRecallCompanyReasonWhere
CLASS IIMinivelle (estradiol transdermal system) Delivers recalledMinivelleNoven PharmaceuticalsPotency & AssayNationwide

More recalls from Noven Pharmaceuticals

All 51

Other Estradiol recalls

All 71